<DOC>
	<DOC>NCT01351038</DOC>
	<brief_summary>This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.</brief_summary>
	<brief_title>Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocarcinoma T24 NX M0 disease ECOG performance status 01 adequate hematological status adequate renal function adequate hepatic function adequate metabolic function pregnant or breast feeding women previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix arterial or venous thromboembolism within 6 months before enrollment clinically significant cardiovascular disease within 1 year before enrollment history of interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>